




















































































































































































































































































































































































































































































































































































































each	 clinicopathological	 variable;	 the	 table	 does	 not	 include	 the	 number	 of	 observations	 where
clinicopathological	data	were	not	available.	The	frequency	of	observed	clinicopathological	variables	is




Variable Trx	(cytoplasmic) 	 Trx	(nuclear) 	 TxNIP
Low High P-value 	 Low High P-value 	 Low High
Age 	 	 	 	 	 	 	 	 	 	
≤	60	years 17	(13.1) 25	(19.2) 0.865 	 18	(13.8) 24	(18.5) 0.401 	 16	(11.9) 30	(22.4)
>	60	years 37	(28.5) 51	(39.2) 	 	 31	(23.8) 57	(43.8) 	 	 17	(12.7) 71	(53.0)
Gender 	 	 	 	 	 	 	 	 	
Male 26	(19.8) 47	(35.9) 0.144 	 25	(19.1) 48	(36.6) 0.402 	 17	(12.6) 57	(42.2)
Female 28	(21.4) 30	(22.9) 	 	 24	(18.3) 34	(26.0) 	 	 17	(12.6) 44	(32.6)
Tumour	size 	 	 	 	 	 	 	 	 	
≤	2cm2 16	(12.3) 32	(24.6) 0.187 	 18	(13.8) 30	(23.1) 0.917 	 11	(8.20) 39	(29.1)
>	2cm2 37	(28.5) 45	(34.6) 	 	 30	(23.1) 52	(40.0) 	 	 23	(17.2) 61	(45.5)
Tumour	stage 	 	 	 	 	 	 	 	 	
1 1	(0.8) 2	(1.5) 0.778 	 2	(1.5) 1	(0.8) 0.329 	 0	(0.0) 3	(2.2)
2 11	(8.4) 16	(12.2) 	 	 12	(9.2) 15	(11.5) 	 	 5	(3.7) 23	(17.0)
3 41	(31.3) 55	(42.0) 	 	 32	(24.4) 64	(48.9) 	 	 28	(20.7) 71	(52.6)
4 1	(0.8) 4	(3.1) 	 	 3	(2.3) 2	(1.5) 	 	 1	(0.7) 4	(3.0)
Node	status 	 	 	 	 	 	 	 	 	
Negative 17	(13.5) 29	(23.0) 0.456 	 17	(13.5) 29	(23.0) 0.937 	 27	(20.9) 22	(17.1)
Positive 35	(27.8) 45	(35.7) 	 	 29	(23.0) 51	(40.5) 	 	 40	(31.0) 40	(31.0)
Venous	invasion 	 	 	 	 	 	 	 	
Absent 21	(16.2) 29	(22.3) 0.821 	 22	(16.9) 28	(21.5) 0.186 	 11	(8.2) 41	(30.6)
Present 32	(24.6) 48	(36.9) 	 	 26	(20.0) 54	(41.5) 	 	 23	(17.2) 59	(44.0)
Perineural	invasion 	 	 	 	 	 	 	 	
Absent 21	(16.0) 36	(27.5) 0.371 	 26	(19.8) 31	(23.7) 0.088 	 9	(6.7) 49	(36.3)
Present 33	(25.2) 41	(31.3) 	 	 23	(17.6) 51	(38.9) 	 	 25	(18.5) 52	(38.5)
	
Table	 3.	 Associations	 between	 TrxR	 protein	 expression	 and	 clinicopathological	 variables	 in	 the	 bile
duct	and	ampullary	carcinoma	cohort.	The	number	of	observations	 for	 the	cohort	 is	shown	 for	each
clinicopathological	 variable;	 the	 table	 does	 not	 include	 the	 number	 of	 observations	 where
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clinicopathological	data	were	not	available.	The	frequency	of	observed	clinicopathological	variables	is
noted	 next	 to	 the	 variable	 subgroup.	 The	 P-values	 are	 resultant	 from	 Pearson	 Chi	 Square	 test	 of
association	(χ2)	or	Fisher’s	Exact	test	in	a	2×2	table	if	a	cell	count	was	less	than	5	(indicated	by	*).
Significant	P-values	are	indicated	by	bold	font.
Variable 	 	 TrxR		(cytoplasmic) 	 TrxR		(nuclear)
	 	 Low High P-value 	 Low High P-value
Age 	 	 	 	 	 	 	 	 	
≤	60	years 	 	 41	(30.6) 4	(3.00) 0.773* 	 30	(22.4) 15	(11.2) 0.024
>	60	years 	 	 79	(59.0) 10	(7.50) 	 	 41	(30.6) 48	(35.8) 	
Gender 	 	 	 	 	 	 	 	 	
Male 	 	 68	(50.4) 8	(5.90) 0.946 	 37	(27.4) 39	(28.9) 0.219
Female 	 	 53	(39.3) 6	(4.40) 	 	 35	(25.9) 24	(17.8) 	
Tumour	size 	 	 	 	 	 	 	 	 	
≤	2cm2 	 	 47	(35.1) 5	(3.70) 0.802 	 30	(22.4) 22	(16.4) 0.385
>	2cm2 	 	 73.1(54.5)
9	(6.70) 	 	 41	(30.6) 41	(30.6) 	
Tumour	stage 	 	 	 	 	 	 	 	 	
1 	 	 3	(2.2) 0	(0.0) 0.100 	 2	(1.5) 1	(0.7) 0.461
2 	 	 23	(17.0) 4	(3.0) 	 	 14	(10.4) 13	(9.6) 	
3 	 	 92	(68.1) 8	(5.9) 	 	 55	(40.7) 45	(33.3) 	
4 	 	 3	(2.2) 2	(1.5) 	 	 1	(0.7) 4	(3.0) 	
Node	status 	 	 	 	 	 	 	 	 	
Negative 	 	 9	(7.0) 38	(29.5) 0.326 	 43	(33.3) 6	(4.7) 0.522
Positive 	 	 22	(17.1) 60	(46.5) 	 	 73	(56.6) 7	(5.4) 	
Venous	invasion 	 	 	 	 	 	 	 	
Absent 	 	 44	(32.8) 5	(3.7) 0.944 	 35	(26.1) 14	(10.4) 0.001
Present 	 	 76	(56.7) 9	(6.7) 	 	 36	(26.9) 49	(36.3) 	
Perineural	invasion 	 	 	 	 	 	 	
Absent 	 	 48	(36.5) 9	(6.7) 0.077 	 37	(27.4) 20	(14.8) 0.021






A PAD	cohort P		value EXP(B) 95.0%	CI	for	EXP(B)
Lower Upper
	 Cytoplasmic	Trx	expression 0.102 0.5 0.218 1.146
	 Gender 0.579 1.178 0.662 2.096
	 T	stage 0.493 0.772 0.368 1.619
	 Node	status 0.113 1.727 0.878 3.398
	 Venous	invasion 0.833 1.068 0.581 1.962
	 Prenural	invasion 0.305 1.521 0.682 3.392
	 Tumour	size 0.221 1.825 0.697 4.784
	 Patient	age 0.804 0.929 0.518 1.666
	 Grade 0.874 1.045 0.608 1.796
B PAD	cohort P		value EXP(B) 95.0%	CI	for	EXP(B)
Lower Upper
	 Nuclear	Trx	expression <0.0001 0.324 0.177 0.592
	 Gender 0.182 1.482 0.831 2.64
	 T	stage 0.99 1.004 0.497 2.031
	 Node	status 0.015 2.353 1.178 4.698
	 Venous	invasion 0.292 1.412 0.744 2.679
	 Prenural	invasion 0.985 1.008 0.458 2.217
	 Tumour	size 0.132 2.202 0.788 6.155
	 Patient	age 0.601 1.176 0.642 2.154
	 Grade 0.644 1.135 0.664 1.94
Table	5.	Multivariate	Cox	Regression	analysis	of	factors	associated	with	overall	survival	in	carcinomas
of	 the	bile	duct	and	ampulla.	Exp	 (B)	 is	used	 to	denote	hazard	 ratio,	and	95%	CI	 is	used	 to	denote
95%	confidence	interval.	Significant	P-values	are	indicated	by	bold	font.
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Bile	duct	and	ampullary	cancer	cohort P		value EXP(B) 95.0%	CI	for	EXP(B)
Lower Upper
TxNIP	expression 0.013 0.548 0.34 0.882
T	stage 0.063 1.634 0.974 2.741
Node	status 0.054 1.586 0.992 2.537
Venous	invasion 0.916 0.975 0.606 1.568
Prenural	invasion 0.251 1.309 0.827 2.073
Grade 0.05 1.5 0.999 2.251
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Legend	of	supplementary	tables:
Supplementary	Table	1:		Associations	between	Trx	and	TxNIP	protein	expression	and
various	clinicopathological	variables	in	the	PAD	cohort.	The	number	of	observations	for	the
cohort	is	shown	for	each	clinicopathological	variable;	the	table	does	not	include	the	number	of
observations	where	clinicopathological	data	were	not	available.	The	frequency	of	observed
clinicopathological	variables	is	noted	next	to	the	variable	subgroup.	The	P-values	are	resultant	from
Pearson	Chi	Square	test	of	association	(χ2)	or	Fisher’s	Exact	test	in	a	2×2	table	if	a	cell	count	was	less
than	5	(indicated	by	*).
Supplementary	Table	2:	Associations	between	TrxR	protein	expression	and	various
clinicopathological	variables	in	the	PAD	cohort.	The	number	of	observations	for	the	cohort	is
shown	for	each	clinicopathological	variable;	the	table	does	not	include	the	number	of	observations
where	clinicopathological	data	were	not	available.	The	frequency	of	observed	clinicopathological
variables	is	noted	next	to	the	variable	subgroup.	The	P-values	are	resultant	from	Pearson	Chi	Square
test	of	association	(χ2)	or	Fisher’s	Exact	test	in	a	2×2	table	if	a	cell	count	was	less	than	5	(indicated
by	*).
Legend	of	supplementary	figures:
Supplementary	Figure	1:	Specificity	of	Trx,	TrxR	and	TxNIP	antibodies.	Lysates	from	(1)
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PANC-1,	(2)	MIA	Paca-2	and	(3)	BxPc-3,	(4)	MDA-MB-231	and	(5)	MCF-7	cancer	cell	lines	were
subjected	to	ECL-Western	blot	to	assess	the	specificity	of	Trx,	TrxR	and	TxNIP	antibodies.
Supplementary	Figure	2:	Representative	photomicrographs	of	protein	expression.	A,	B	and
C	are	negative	controls	of	PC	tissue	sections	representing	PAD,	bile	ductal	and	ampullary	carcinomas
respectively.	D,	E	and	F	are	expression	of	Trx,	TrxR	and	TxNIP	in	PADs	respectively.	G,	H	and	I	are
expression	of	Trx,	TrxR	and	TxNIP	in	bile	ductal	carcinomas	respectively.	J,	K	and	L	are	expression	of
Trx,	TrxR	and	TxNIP	in	ampullary	carcinomas	respectively.	Photomicrographs	are	at	10x	magnification
with	20x	magnification	inset	box	where	scale	bar	shows	200μm.
Figures
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Figure	1
Representative	photomicrographs	of	different	staining	patterns	of	Trx	system	protein
expression	from	PAD	TMAs.	(A)	benign	pancreatic	tissue,	(B)	weak	staining	of	Trx,	(C)
moderate	staining	of	Trx,	(D)	strong	staining	of	Trx,	(E)	weak	cytoplasmic	staining	with
moderate	nuclear	staining	of	Trx,	(F)	weak	cytoplasmic	staining	of	TxNIP,	(G)	strong
cytoplasmic	staining	of	TxNIP,	(H)	weak	staining	of	TrxR,	(I)	moderate	staining	of	TrxR.
Photomicrographs	are	at	10x	magnification	with	20x	magnification	inset	box	where	scale
bar	shows	200μm.	Abbreviation:	CS=Cytoplasmic	H-score,	NS=	Nuclear	H-score.
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Figure	2
Kaplan-Meier	analysis	of	overall	survival	showing	the	impact	of	Cytoplasmic	Trx	(A),	nuclear
Trx	(B),	cytoplasmic	TrxR	(C),	nuclear	TrxR	(D)	and	cytoplasmic	TxNIP	(E)	expression	in	the
PAD	cohort	with	significance	determined	using	the	log-rank	test.
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Figure	3
Kaplan-Meier	analysis	of	overall	survival	showing	the	impact	of	Cytoplasmic	Trx	(A),	nuclear
Trx	(B),	cytoplasmic	TrxR	(C)	and	nuclear	TrxR	(D)	and	cytoplasmic	TxNIP	(E)	expression	in
the	bile	duct	and	ampullary	carcinoma	cohort	with	significance	determined	using	the	log-
rank	test.
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Figure	4
Kaplan–Meier	overall	survival	analysis	between	different	subgroups	of	Trx	expression	in	the
bile	duct	and	ampullary	cohort.	Kaplan-Meier	analysis	of	overall	survival	based	upon
expression	profiles.	Low	nuclear/high	cytoplasmic	expression	showed	longer	overall	survival
than	other	three	subgroups	either	against	each	separate	subgroup	(A)	or	when	the	three
subgroups	were	combined	(B).
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